CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 249 enrolled
Drug / intervention
Posaconazoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05065658
NCT05065658N/ACompleted
CompareCT.gov

Posaconazole for the Prevention of COVID-19 Associated Pulmonary Aspergillosis in Critically-Ill Patients: A European Multicenter Case-Control Study

Medical University of Graz·observational·Posted Oct 4, 2021·Updated Feb 17, 2025

In Brief

An observational study evaluating Posaconazole for COVID-19 Respiratory Infection and Aspergillosis. Completed, enrolled 249 participants across 3 sites in 3 countries.

Detailed Summary

COVID-19 associated pulmonary aspergillosis (CAPA) is considered a potentially life-threatening infection in critically ill COVID (Corona Virus disease)-19 patients. This study will investigate the efficacy of mold-active prophylaxis with posaconazole for patients with severe SARS (severe acute respiratory syndrome)-CoV-2 infection admitted to the ICU (intensive care unit) in a multi-center case-control study in Europe.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19 Respiratory Infection, Aspergillosis
CountriesAustria, France, Italy
CollaboratorsMerck Sharp & Dohme LLC

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedOct 4, 2021
Enrollment StartMar 1, 2020
Primary CompletionAug 23, 2023
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 4.7 years ago

Interventions

Posaconazoledrug

Intravenous posaconazole prophylaxis